Share This Page
Drugs in MeSH Category Excipients
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | THAM | tromethamine | SOLUTION;INJECTION | 013025-002 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| B Braun Medical | TROMETHAMINE | tromethamine | SOLUTION;INJECTION | 211558-001 | Dec 9, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Milla Pharms | TROMETHAMINE | tromethamine | SOLUTION;INJECTION | 213116-001 | Dec 31, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Excipients
Summary
This report provides a comprehensive analysis of market trends and the patent landscape for pharmaceuticals classified under the NLM MeSH (Medical Subject Headings) class: Excipients. Excipients, inert substances used alongside active pharmaceutical ingredients (APIs), are critical in drug formulation, influencing stability, bioavailability, and patient adherence. Despite their inert designation, excipients are becoming increasingly innovative, with evolving regulatory and patent policies affecting market dynamics. This report explores current market size, growth drivers, key players, patent expiry trends, recent innovations, and strategic considerations for stakeholders.
What Are Excipients and Why Do They Matter?
Definition and Role
Excipients are inactive substances formulated with APIs in medication production, serving functions such as:
- Fillers or bulking agents
- Binders
- Disintegrants
- Lubricants
- Preservatives
- Stabilizers
While traditionally viewed as inert, recent innovations have positioned certain excipients as active or functional excipients that influence drug efficacy and delivery mechanisms.
Regulatory Framework
- FDA & EMA Regulations: Excipients are subject to stringent safety assessments, categorized as either generally recognized as safe (GRAS) or under specific approval pathways.
- IP Policy: Patents generally cover API compounds; however, excipient innovations can patent formulations, delivery systems, or manufacturing processes—driving the patent landscape.
Market Size and Growth Trends
| Parameter | Value/Trend |
|---|---|
| Global Excipient Market Size (2022) | USD 8.2 billion |
| Expected CAGR (2023–2028) | 6.1% |
| Key Regions | North America (35%), Europe (25%), Asia-Pacific (30%), Rest of World (10%) |
| Major End-User Sectors | Generic drugs (45%), Biosimilars (15%), Branded drugs (40%) |
Sources: Data from MarketsandMarkets[1], Grand View Research[2].
Drivers of Growth
- Growth in Generic and Biosimilar Markets: Excipients tailored for biosimilar formulations are gaining prominence.
- Regulatory Advances: Streamlined approval processes for novel excipients.
- Technological Innovations: Development of multifunctional excipients enhances drug efficacy.
- Expanded Indications: Excipients enabling formulations for complex delivery routes (e.g., transdermal, nasal).
Patent Landscape: Key Players and Trends
Patent Assignees and Innovators
| Top Patent Holders (2022–2023) | Portfolio Highlights | Patent Life (approx.) |
|---|---|---|
| BASF SE | Functional excipients, sustained-release matrices | 2024–2034 |
| Dow Chemical Company | Novel polymers for drug delivery | 2025–2035 |
| Ashland Global Holdings | Multifunctional excipients | 2023–2033 |
| Boehringer Ingelheim | Bio-specific excipients and stabilizers | 2022–2032 |
| JRS Pharma | Co-processed excipient systems | 2022–2030 |
Patent Trends:
- Incremental Innovation: Focus on co-processed and multifunctional excipients for enhanced performance.
- Formulation Patents: Cover specific combinations of excipients with APIs.
- Delivery-system Patents: Excipients enabling novel delivery routes (e.g., nanostructures, mucoadhesive systems).
Patent Expiry and Litigation Trends
| Year | Number of Key Excipients Patents Expiring | Notes |
|---|---|---|
| 2024–2026 | 15–20 patents | Increased patent expiries, open market opportunities |
| 2027–2029 | 25–30 patents | Patent cliff for major excipient formulations |
Patent expiries in the next 2–3 years are poised to accelerate generics and biosimilars development, incentivizing innovation pathways.
Innovations and Emerging Trends
Functional and Active Excipients
- Smart Excipients: Responsive to pH, temperature, or enzymatic environments.
- Health-Enhancing Excipients: Incorporating bioactivity (e.g., antioxidants, anti-inflammatory agents).
- Biodegradable Polymers: For controlled release and targeted delivery.
Regulatory and Policy Impacts
- FDA’s Inactive Ingredient Database: Increasing transparency and safety oversight.
- EU’s Novel Food Framework: Potentially applicable to certain excipients.
- IP Policy Shifts: Encouraging patent filings for formulation innovations over traditional chemical entities.
Market Entry Strategies
- Collaborations with academia for novel excipient research.
- Patent filing for formulation-specific innovations.
- Focused development on excipients for niche markets (e.g., pediatric, geriatric, targeted drug delivery).
Competitive Landscape and Strategic Considerations
Major Industry Players
| Company | Core Strengths | Notable Patent Initiatives |
|---|---|---|
| BASF SE | Broad portfolio, global manufacturing | Smart excipient systems, co-processed excipients |
| Dow | Innovative polymers, delivery platforms | Release-modulation excipients |
| Ashland | Custom formulations, bioavailability enhancers | Multifunctional excipients |
Key Market Players' Strategies
- Innovation Focus: R&D investment in functional excipients.
- Intellectual Property (IP): Active pursuit of formulation patents.
- Collaborations: Partnerships with pharma companies for tailored excipient solutions.
- Geographic Expansion: Focus on emerging markets with rising pharma R&D activity.
Barriers to Entry
- Stringent regulatory requirements for excipient safety.
- High cost of R&D and patent filing.
- Established patent protections for key excipients.
Comparative Analysis: Patent Landscape vs. Market Dynamics
| Aspect | Patent Landscape | Market Dynamics |
|---|---|---|
| Innovation Focus | Novel formulations, delivery systems | Expanding application spectrum, biocompatibility |
| Patent Expiry Impact | Expiries lead to generics and innovation opportunities | Market growth accelerates with patent expiries |
| Regulatory Influence | Stricter safety and quality regulations | Demand for high-quality, compliant excipients |
| Competitive Strategies | R&D, IP filings, partnerships | Product differentiation, niche targeting |
Regulatory Implications and Policy Frameworks
| Regulation/Policy | Impact on Excipients Market | Key Aspects |
|---|---|---|
| FDA Inactive Ingredient Database | Transparency, safety assurance | Listing status influences market acceptance |
| EMA Guidance on Excipients | Safety and quality standards | Harmonization with US standards |
| Patent Policies | Incentivize innovation | Duration, patentability criteria |
Future Outlook
- Innovation Trajectory: Growing role of functional, bioactive, and delivery-enhancing excipients.
- Market Expansion: Expected CAGR of ~6% through 2028; increasing adoption in biosimilars.
- Patent Strategies: Focus on formulation-specific patents to extend market exclusivity.
- Regulatory Evolution: Potential for accelerated approval pathways for novel excipients.
Key Takeaways
- The excipient market is expanding, driven by increased application in biosimilars, novel drug delivery systems, and innovative formulations.
- Patents serve as crucial strategic assets, with major players actively filing for formulation-specific and delivery system excipients.
- The upcoming patent expiries (2024–2026) will open opportunities for generics and innovative manufacturers.
- Regulatory frameworks favor innovative excipients that improve safety, efficacy, and delivery, influencing market entry.
- Successful market positioning depends on R&D investment, IP strategy, and understanding evolving regulatory policies.
FAQs
1. How does patenting influence excipient development?
Patents protect formulation innovations, enabling exclusivity and recoupment of R&D investments. Patent filings are increasingly focused on multifunctional and delivery-specific excipients, shaping competitive advantage.
2. Are all excipients patented?
No. Many traditional excipients are off-patent; however, novel formulations, manufacturing processes, and delivery systems involving excipients are patentable.
3. What regulatory challenges face excipient innovations?
New excipients must demonstrate safety and efficacy, often requiring extensive testing and approval, which can delay market entry and increase costs.
4. Which regions dominate excipient patents and markets?
North America and Europe lead in patent filings and market size, but Asia-Pacific exhibits rapid growth due to expanding manufacturing and R&D activities.
5. What role will biodegradable and bioactive excipients play in the future?
They are poised to enhance drug delivery, reduce environmental impact, and enable targeted therapies, representing a significant segment of innovation within excipients.
References
[1] MarketsandMarkets, “Excipients Market by Type,” 2022.
[2] Grand View Research, “Pharmaceutical Excipients Market Analysis,” 2022.
More… ↓
